Royalty Pharma (RPRX) Retained Earnings (2019 - 2026)

Royalty Pharma has disclosed Retained Earnings across 8 years of filings, most recently posting $2.5 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at $2.5 billion, up 1.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 1.07% YoY), and the FY2025 annual result was $2.4 billion, down 17.2% from the prior year.
• Retained Earnings came in at $2.5 billion for Q1 2026 at Royalty Pharma, up from $2.4 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $2.8 billion in Q4 2024 to a low of $12.3 million in Q1 2022.
• The 5-year median for Retained Earnings is $2.4 billion (2025), against an average of $2.1 billion.
• Across the five-year window, Retained Earnings tumbled 99.43% in 2022 and soared 17916.99% in 2023, its largest moves.
• Royalty Pharma's Retained Earnings stood at $2.0 billion in 2022, then increased by 28.14% to $2.5 billion in 2023, then climbed by 13.03% to $2.8 billion in 2024, then declined by 17.2% to $2.4 billion in 2025, then advanced by 6.4% to $2.5 billion in 2026.
• The last three Retained Earnings figures came in at $2.5 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.